Quick Answer
DNA X, Inc. reported Operating Income of -$33.64 million for fiscal year 2024.
DNA X, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$33.64M | -6657.3% |
| 2023 | $513.0K | +103.6% |
| 2022 | -$14.29M | +62.4% |
| 2021 | -$38.00M | -29.9% |
| 2020 | -$29.26M | -30.7% |
| 2019 | -$22.38M | -514.9% |
| 2018 | $5.39M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.98M | -67.5% | +40.9% |
| June 30, 2025 | -$6.73M | -4.0% | -1143.7% |
| March 31, 2025 | $645.0K | +124.0% | +127.1% |
| September 30, 2024 | -$2.38M | -445.3% | +63.3% |
| June 30, 2024 | -$6.47M | -966.1% | -140.6% |
| March 31, 2024 | -$2.69M | -907.5% | -490.8% |
| September 30, 2023 | $688.0K | +135.7% | -7.9% |
| June 30, 2023 | $747.0K | +117.7% | +124.3% |
- DNA X, Inc. showed a decrease of -6657.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2024 period, DNA X, Inc.’s operating income has declined by 723.6% (from $5.39 million to -$33.64 million).
- The most recent figure is from DNA X, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: